For non-commercial use only
TAKEDA PHARMACEUTICALS
PROTOCOL
A Randomized, Double -blind, Placebo -Controlled Study to Evaluate the Efficacy, Safety, and 
Tolerability of TAK -861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Study to Evaluate the Efficacy, Safety, and Tolerability of TAK -861 for the Treatment of 
Narcolepsy With Cataplexy 
Sponsor: Takeda Development Center Americas, Inc.
95 Hayden Avenue
Lexington, MA 02421 USA
Study Number: TAK-861-2001
Study Phase: 2
IND Number: 154232 EudraCT/CTIS 
Number:2022 -001654 -38
ClinicalTrials.gov: Posting planned prior 
tostudy startWHO Universal Trial 
Number:U1111 -1277 -4261
Investigational 
Product:TAK-861
Date: 17Aug 2022 Version/Amendment 
Number:Initial version
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confident ial communicat ion of Takeda . Acceptance of this document 
constitutes the agreement by  the recipient that no informat ion contained herein will be published 
or disclosed wi thout wri tten authori zation from Takeda . Furthermore, the informat ion is only 
meant for review and co mpliance by  the recipient, his or her staff, and applicable inst itutional 
review co mmit tee and regulatory  agencies to enable conduct of the study .
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 3of 115
Protocol 17Aug 2022
CONFIDENTIALINVESTIGATOR AGREEMENT 
I confirm that I have read and understand this protocol, the invest igator’s brochure (IB), 
prescribing information, and any other product information provided by the sponsor. I agree to 
conduct thi s study  in accordance wit h the requirements of this protocol and also to protect the 
rights, life, dignit y, integri ty, confident iality of personal informat ion, safety , privacy, and well -
being of study  parti cipants in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
ICH GCP.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and
regul ations.
Regulatory  requi rements for reporting serious adverse events (SAEs) as defined in this
protocol .
Terms outlined in the clinical study  site agreement.
Responsibilit ies o f the invest igator as described in this protocol.
I understand that the informat ion in this protocol is confident ial and shoul d not be disclosed, 
other than to those direct ly involved in the execut ion or the scient ific/ethical review of the study , 
without wri tten authori zation from the sponsor. It is, however, permissible to provide the 
inform ation contained herein to a potential part icipant to obtain their informed consent to 
participate.
I understand that failure to comply  with the requi rements of the protocol may  lead to the 
termination o f my participat ion as an invest igator for this study.
I understand that the sponsor may decide to suspend or prem aturely terminate the study  at any  
time for whatever reason; such a decisio n will be communicated to me in writ ing. Conversely, 
shoul d I deci de to wi thdraw from  execut ion of the study , I will communicate my intent ion 
immediately  in wri ting to the sponsor.
Signature of Investigator Date
Investigator Name (print or type)
Investigator’s Title
Name and Location of Facility (City, State/Province)
Location of Facility (Country)
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 4of 115
Protocol 17Aug 2022
CONFIDENTIALADMINISTRATIVE INFORMATION 
CONTACTS
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in relevant guidelines provided to the site.
Takeda Development Center Americas, Inc. –sponsored invest igators will be provided with 
emergency medical contact information cards to be provided to each study  parti cipant and 
carried by each participant p er individual country requirements.
ADDITIONAL INFORMATI ON 
A separate contact informat ion list will be provided to each site.
Contact Type/Role Contact
Serious adverse event and pregnancy reporting Pharmacovigilance
Takeda Development Center Americas, Inc.
Fax: +1 224-554-1052
Email: PVSafetyAmericas@tpna.com
24-hour urgent medical contact North America: +1 888 483 7729 
Europe, Middle East and Africa/Asia Pacific: +44 122 337 
4240
PRODUCT QUALITY COMP LAINTS
A product qualit y complaint is any  written, el ectronic, or oral  comm unicati on that alleges 
deficiencies related to the identit y, qualit y, durability , reliabilit y, safet y, strength, purit y, 
effect iveness, or performance of a product, device, or combinat ion product after it is released for 
distribut ion. 
Report product complaints using the form called “Clinical Trial Material Complaint Form.” 
Send it to the fo llowing email  address: 
ctmcomplaint@takeda.com
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 5of 115
Protocol 17Aug 2022
CONFIDENTIALTABLE OF CONTENTS
APPROVALS ............................................................................................................................. 2
ADMINISTRATIVE INFOR MATION ....................................................................................... 4
ADDITIONAL INFORMATI ON................................................................................................ 4
PRODUC T QUALITY COMPLAINTS ...................................................................................... 4
TABLE OF CONTENTS ............................................................................................................ 5
1. PROTOCOL SUMMARY ............................................................................................. 12
1.1 Synopsis .................................................................................................................. 12
1.2 Schema .................................................................................................................... 21
1.3 Schedule of Act ivities.............................................................................................. 22
2. INTRODUCTION ......................................................................................................... 29
2.1 Study  Rati onale ....................................................................................................... 29
2.2 Background ............................................................................................................. 29
2.2.1. Summary  of Nonclinical Data .......................................................................... 30
2.2.2. Summary  of Effects in Humans ....................................................................... 30
2.3 Benefit -Risk Assessment ......................................................................................... 33
2.3.1. Potenti al Benefi ts............................................................................................. 33
2.3.2. Potenti al Risks .................................................................................................33
3. OBJECTIVES, ENDPOINT S........................................................................................ 34
3.1 Object ives and Endpo ints......................................................................................... 34
3.2 Estimands ................................................................................................................ 36
4. STUDY DESIGN .......................................................................................................... 36
4.1 Overall Design ......................................................................................................... 36
4.2 Scientific Rationale for Study  Design ...................................................................... 37
4.2.1. Rationale for Study  Popul ation........................................................................ 37
4.2.2. Rationale for Study  Design .............................................................................. 37
4.2.3. Rationale for Endpoints ................................................................................... 38
4.2.3.1. Safety Endpo ints...................................................................................... 38
4.2.3.2. Efficacy Endpo ints.................................................................................. 38
4.2.4. Parti cipant Input into Desi gn............................................................................ 39
4.3 Justification for Dose ............................................................................................... 39
4.4 End of Study /Study  Com pletion Definit ion.............................................................. 39
5. STUDY POPULATION ................................................................................................ 39
5.1 Inclusio n Cri teria..................................................................................................... 39
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 6of 115
Protocol 17Aug 2022
CONFIDENTIAL5.2 Exclusion Criteria.................................................................................................... 41
5.3 Lifest yle Considerat ions.......................................................................................... 45
5.3.1. Meals and Dietary  Restri ctions........................................................................ 45
5.3.2. Activity........................................................................................................... 46
5.3.3. Contraception for Participants of Childbearing Potent ial or Capable o f 
Producing Viable Sperm .................................................................................. 46
5.4 Screening ................................................................................................................. 46
5.4.1. Screen Failures ................................................................................................ 46
5.5 Criteria for Temporarily Delaying Randomizat ion................................................... 47
5.6 Enrollment ............................................................................................................... 47
6. STUDY INTERVENTION(S ) AND CONCOMITANT THERAPY .............................. 47
6.1 Study  Intervent ions Administered ............................................................................ 47
6.2 Preparati on, Handling, Storage, and Accountabilit y................................................. 48
6.2.1. Accountabilit y Throughout the Study ............................................................... 48
6.2.2. Receiving Product at the Site ........................................................................... 49
6.2.3. Labeling .......................................................................................................... 49
6.2.4. Dispensing/Administration .............................................................................. 49
6.2.4.1. Dispensing ............................................................................................... 49
6.2.4.2. Administrati on......................................................................................... 49
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ....................................... 51
6.3.1. Randomization .................................................................................................51
6.3.2. Blinding the Treatment Assignment .................................................................51
6.3.3. Unblinding ....................................................................................................... 51
6.4 Study  Drug Com pliance ........................................................................................... 51
6.5 Dose Modificat ion................................................................................................... 51
6.6 Continued Access to Study  Intervent ion after the End of the Study .......................... 51
6.7 Treatment of Overdose ............................................................................................ 51
6.8 Concomitant Therapy ............................................................................................... 52
6.8.1. Excluded Treatments ....................................................................................... 52
6.8.2. Permi tted Concomitant Medications ................................................................ 54
7. DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL ...................................................................... 54
7.1 Discontinuati on of  Study  Intervent ion...................................................................... 54
7.2 Parti cipant Discontinuation/Wit hdrawal fro m the Study ........................................... 56
7.3 Lost to Follow -up.................................................................................................... 56
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 7of 115
Protocol 17Aug 2022
CONFIDENTIAL8. STUDY ASSESSMENTS AN D PROCEDURES .......................................................... 56
8.1 Dem ographics, Medi cal History , Medicati on History  and Administrative 
Procedures ............................................................................................................... 57
8.1.1. Dem ographics .................................................................................................. 57
8.1.2. Medical History ............................................................................................... 57
8.1.3. Prior and Conco mitant Treatments/Medications ............................................... 58
8.1.4. Diagnostic Cri teria/Disease Classificat ion........................................................ 58
8.1.4.1. Diagnostic Cri teria for NT1 ................................
..................................... 58
8.1.4.2. HLA Genoty ping ..................................................................................... 59
8.1.5. Administrative Procedures (Contingency Measures for Unavoidable 
Circumstances) ................................................................................................ 59
8.2 Efficacy Assessments ............................................................................................... 61
8.2.1. Primary Efficacy  Measurement ........................................................................ 61
8.2.2. Other ............................................................................................................... 61
8.2.2.1. ....................................................................................................... 61
8.2.2.2. ............................................................................ 61
8.2.2.3. Clinical Outcome Assessments ................................................................ 62
8.3 Safety Assessments .................................................................................................. 65
8.3.1. Physical Examinat ions..................................................................................... 65
8.3.2. Vital Signs....................................................................................................... 65
8.3.2.1. Weight, Height, and BMI ......................................................................... 66
8.3.3. ECG ................................................................................................................ 66
8.3.4. Clinical Safety  Laboratory  Tests ...................................................................... 67
8.3.5. Pregnancy Testing ........................................................................................... 68
8.3.6. Suicidal  Ideat ion and Behavior Risk Monitoring .............................................. 68
8.3.7. Other ............................................................................................................... 68
8.3.7.1. .................................................................... 68
8.3.7.2. ..................................................................................................... 68
8.3.8. AEs, SAEs, and Other Safet y Reporting .......................................................... 68
8.3.8.1. Time Period and Frequency  for Collect ing AE and SAE Informat ion....... 69
8.3.8.2. Method of Detecting AEs and S AEs ........................................................ 69
8.3.8.3. Follow-up of  AEs and SAEs .................................................................... 69
8.3.8.4. Regulatory  Reporting Requirements for SAEs ......................................... 69
8.3.8.5. Pregnancy in a Participant or Participant’s Partner During the Study ....... 70
8.3.8.6. AEs of Special Interest ............................................................................ 70
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 8of 115
Protocol 17Aug 2022
CONFIDENTIAL8.4 ........................................................................................................................... 70
8.4.1. .................................................................71
8.5 Genet ics................................................................................................................... 71
8.5.1. .......................................................................... 71
8.5.2. HLA Genoty ping ............................................................................................. 72
8.6 ...................................................................................... 72
8.7 Immunogenicit y Assessments .................................................................................. 72
9. STATISTICAL CONSIDER ATIONS ........................................................................... 72
9.1 Statistical Hypotheses .............................................................................................. 72
9.1.1. Primary Endpo int............................................................................................. 72
9.1.2. Secondary  Endpo ints....................................................................................... 72
9.2 Analysis Sets ........................................................................................................... 73
9.2.1. Safety Set........................................................................................................ 73
9.2.2. ............................................................................................................. 73
9.2.3. Full Analysis Set .............................................................................................. 73
9.3 Efficacy Analyses .................................................................................................... 73
9.3.1. Primary Efficacy  Endpoint ............................................................................... 73
9.3.2. Secondary  Efficacy  Endpoints ......................................................................... 73
9.3.3. ................................................................................... 73
9.4 Safety Analyses ....................................................................................................... 74
9.5 Other Analyses ........................................................................................................ 74
9.5.1. .................................................................................................... 74
9.5.2. .............................................................................................. 74
9.6 .................................................................................. 74
9.7 .................................................................................. 75
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS ....76
10.1 Regulatory , Ethical , and Study  Oversight Consi derati ons......................................... 76
10.1.1. Regulatory  and Ethi cal Considerat ions............................................................. 76
10.1.2. Financial Disclo sure ........................................................................................ 76
10.1.3. Inform ed Consent Process ............................................................................... 76
10.1.4. Data Protection ................................................................................................ 77
10.1.4.1. Notice Regarding the Use and Transfer of the Investigator’s Personal 
Inform ation.............................................................................................. 78
10.1.5. Committees Structure ...................................................................................... 80
10.1.5.1. IRB and/or IEC Approval ........................................................................ 80
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 9of 115
Protocol 17Aug 2022
CONFIDENTIAL10.1.5.2. Other Committees .................................................................................... 81
10.1.6. Disseminat ion of Clinical Study  Data .............................................................. 81
10.1.6.1. Study  Results Disclosure ......................................................................... 81
10.1.7. Data Qualit y Assurance ................................................................................... 81
10.1.7.1. Protocol  Deviat ions................................................................................. 82
10.1.7.2. Study -Site Moni toring Visit s................................................................... 82
10.1.7.3. Audits ...................................................................................................... 83
10.1.8. Source Documents ........................................................................................... 83
10.1.8.1. eCRFs ...................................................................................................... 83
10.1.8.2. Docum entati on and Retent ion of Records ................................................ 84
10.1.8.3. Data Handling ......................................................................................... 85
10.1.8.4. Record Retention ..................................................................................... 85
10.1.9. Study  and Si te Start and Cl osure ...................................................................... 86
10.1.9.1. First Act of Recrui tment.......................................................................... 86
10.1.9.2. Study /Site Terminat ion............................................................................ 86
10.1.9.3. Optional Study  Parti cipant Intervi ews...................................................... 88
10.1.10. Publicat ion Policy ............................................................................................ 88
10.1.11. Responsibilit ies o f the Sponsor and the Investigator ......................................... 89
10.1.11.1. Sponsor Responsibilit ies.......................................................................... 89
10.1.11.2. Invest igator Responsibilit ies.................................................................... 90
10.2 Clinical Laboratory  Tests ......................................................................................... 91
10.2.1. Clinical Laboratory  Assessments and Other Safet y Assessments ...................... 92
10.2.2. .................................................. 93
10.3 AEs and SAEs: Definit ions and Procedures for Recording, Evaluating, Follow- up, 
and Reporting .......................................................................................................... 93
10.3.1. Definit ion of AE.............................................................................................. 93
10.3.2. Definit ion of SAE ............................................................................................ 95
10.3.3. Addit ional Considerat ions in Ident ifying and Defining AEs ............................. 96
10.3.3.1. Defining Discrete AEs ............................................................................. 96
10.3.3.2. AEs of Special Interest ............................................................................ 97
10.3.4. Recording and Fo llow-Up of AE and/or SAE .................................................. 98
10.3.4.1. Frequency ................................................................................................ 98
10.3.4.2. Intensit y................................................................................................... 98
10.3.4.3. Causalit y/Relatedness ................................
.............................................. 99
10.3.4.4. Action Taken ......................................................................................... 100
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 10of 115
Protocol 17Aug 2022
CONFIDENTIAL10.3.4.5. Outcom e................................................................................................ 100
10.3.4.6. Follow-Up............................................................................................. 101
10.3.5. Expedited Reporting of SAEs and Selected AEs ............................................ 102
10.3.5.1. ........................... 102
10.3.5.2. Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  
Authori ties............................................................................................. 102
10.4 Contraceptive and Barrier Guidance ....................................................................... 103
10.4.1. Definit ions..................................................................................................... 103
10.4.2. Contraception Guidance ................................................................................. 103
10.4.3. Pregnancy ...................................................................................................... 106
10.5 ...107
10.6 Country -specific Requirements .............................................................................. 108
10.7 Abbreviat ions and Definit ions................................................................................ 109
10.7.1. Abbreviat ions................................................................................................ 109
10.8 Protocol  Amendment Hi story................................................................................. 111
11. REFERENCES ............................................................................................................ 112
LIST OF TABLES
Table 1.a ........................................................................................ 22
Table 1.b ........................ 27
Table 6.a Study  Intervent ion(s) Administered: Drug .......................................................... 48
Table 6.b ........................................... 52
Table 8.a ............................................................................. 57
Table 10.a Protocol -Requi red Laboratory  Tests ................................................................... 92
Table 10.b Acceptable Contraception Methods and Lactation Guidance for this Study ......105
Table 10.c Unacceptable Co ntracepti on Methods .............................................................. 106
Table 10.d ....................................................................................... 108
LIST OF FIGURES
Figure 1.a .................................................................................................... 21
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 12of 115
Protocol 17Aug 2022
CONFIDENTIAL1. Protocol Summary
1.1 Synopsis
Name of Sponsor(s):
Takeda Development Center Americas, Inc.
95 Hayden Avenue
Lexingto n MA 02421
USACompound:
TAK -861
Study Number: 
TAK -861-2001Phase:
2IND No.: 
154232EudraCT No.: 
2022-001654 -38
Title of Protocol: 
A Randomized, Double -blind, Placebo -Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK -
861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Short Title:
A Study  to Evaluate the Efficacy, Safety, and Tolerability of TAK -861 in the Treatment for Narcolepsy With 
Cataplexy 
Number of participants:
A total of approximately 100 participants (20 per arm)
Investigator(s): Multicenter global study
Site(s) and Region(s): Up to approximately 70 sites across North America, Europe, and Asia Pacific
Study Period (planned ): Q1 2023 to Q2 2024
Objectives and Endpoints
Objectives Endpoints
Primary
To assess the effect of TAK -861 on excessive
daytime sleepiness (EDS) as measured by sleep
latency from the Maintenance of Wakefulness
Test (MWT).Change f rom baseline to Week 8 in mean sleep
latency from the MWT
Secondary
To assess the effect of TAK -861 on EDS as
measured by the Epworth Sleepiness Scale
(ESS) total score.Change f rom baseline to Week 8 in ESS total
score
To assess the effect of TAK -861 on cataplexy
as assessed by the weekly cataplexy rate
(WCR).WCR at Week 8
To evaluate the safety and tolerability of TAK -
861.Occurrence of at least 1 treatment -emergent
adverse event (TEAE).
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 13of 115
Protocol 17Aug 2022
CONFIDENTIALAdditional/Exploratory
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 23of 115
Protocol 17Aug 2022
CONFIDENTIAL
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 24of 115
Protocol 17Aug 2022
CONFIDENTIAL 
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 27of 115
Protocol 17Aug 2022
CONFIDENTIALTable 1.b
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 28of 115
Protocol 17Aug 2022
CONFIDENTIALTable 1.b
 
 
 
 
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 48of 115
Protocol 17Aug 2022
CONFIDENTIALTable 6.adescribes the intervent ionsadministered in all arms of this study .
Details regarding the dosage form descript ion and strengths, or composit ion for the 
extem poraneous preparati on, of  the active drug and placebo, can be found in the IB. Study  drug 
will be packaged to support the enrollment of participants as required.
Table 6.a Study Intervention(s) Administered: Drug
Intervention Label TAK -861 Placebo 
Intervention Name TAK -861 Placebo 
Former Name(s) or 
Alias(es)NA NA
Intervention 
DescriptionInformation provided in the IB Information provided in the IB
Excipients Information provided in the IB Information provided in the IB
Type Drug Placebo 
Dose Formulation Tablet Tablet
Unit Dose 
Strength(s)Information provided in the IB Information provided in the IB
Dosage Level(s) See Section 4.3 See Section 4.3
Route of 
AdministrationOral Oral
Use Experimental Placebo
Classification Investigational medicinal product NA
Authorization Status Not autho rized in any region NA
Sourcing Provided centrally  by the sponsor or 
designeeProvided centrally by the sponsor or 
designee
Packaging and 
LabelingInformation provided in pharmacy manual Information provided in pharmacy manual
IB: investigator’s brochure; NA: not applicable.
6.2 Preparation, Handling, Storage, and Accountability 
For preparation, handling, and storage of the sponsor -supplied study  product, refer to the 
pharmacy manual.
6.2.1. Accountability Throughout the Study
The invest igator or designee must ensure that the sponsor -supplied study product i s used in 
accordance with the protocol and is only  dispensed to/used for participants enro lled in the study. 
To document appropriate use of sponsor- supplied study product (Section 6.1), the invest igator or 
designee must maintain 100% accountabilit y for all sponsor -supplied study  intervent ions that the 
site receives and dispenses during their ent ire partici pation in the study . 
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 51of 115
Protocol 17Aug 2022
CONFIDENTIAL6.3 Measures to Minimize Bias: Randomization and Blinding 
6.3.1. Randomization 
Randomization personnel of the sponsor or designee will generate the randomizat ion schedule 
for the IRT sy stem . . Details are in the IRT sy stem  
specifica tions. 
6.3.2. Blinding the Treatment Assignment 
This is a double -blind study; the investigator and participants are blinded to treatment 
assignment. Blinded study  drug supply will be provided, and the standard operating procedures 
of the study  site for maintain ing the double -blind will be fo llowed. 
6.3.3. Unblinding 
The study  drug blind shall not be broken by  the investi gator unl ess inform ation concerning the 
study  drug i s necessary for the medical treatment of the participant. If possible, the sponsor or 
designee (e g, medical  monitor) shoul d be contacted before the blind is broken. Unblinding will 
be perform ed per the standard operating procedures of the study  site.
6.4 Study Drug Compliance
When participants are dosed at the site, they  will receive study  intervent ion under m edical  
supervisio n. The date and time of each dose administered in the clinic will be recorded in the 
source documents and dosing e -diary. The study  parti cipant i dentificat ion will fo llow the 
standard operating procedure of the site and the pharmacy m anual .
When participants take the study  drug at home, they  should record the time of the dose in their 
dosing e -diary  (a com ponent of the e -diary).
Parti cipants m ust be instructed how and where to return unused study  intervent ion and 
empty/used study  interventi on packaging for drug accountabilit y. 
6.5 Dose Modification
6.6 Continued Access to Study Intervention after the End of the Study 
After the completion o f the current study , parti cipants will have the option to participate in an 
LTE study  under a separate protocol (assuming the protocol is open for enrollment).
6.7 Treatment of Overdose 
In thi s study , an overdose i s defined as a known deliberate or accidental administration of the 
study  interventi on, ei ther to or by  a study parti cipant, at a d ose above that assigned to that 
individual part icipant.
In the event of a drug overdose, the participant should be treated symptomat ically.
All cases of overdose or medicat ion error must be documented on the eCRF. Because these 
events are not, in and of th emselves, AEs, they  shoul d be reported regardless of whether any 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 52of 115
Protocol 17Aug 2022
CONFIDENTIALmanifested signs or symptoms are considered AEs. If there are signs and symptoms meeting the 
criteria for reporting as AEs or SAEs, they  shoul d also be reported, as described in Sect ion10.3.
6.8 Concomitant Therapy 
6.8.1. Excluded Treatments
Restricted medications and supplements are shown in Table 6.b. Restri cted m edicat ions may be 
discontinued earlier than, but not later than, the required start of the restrict ion peri od. For 
example, the PI may decide to have participant restrict medicat ions for a l onger peri od before 
baseline to ensure the participa nt’s narcolepsy symptoms have returned to baseline. 
Administrati on of  any drugs used for the treatment of narcolepsy wit h cataplexy (NT1) must be 
discontinued. The invest igator will determine the schedule for tapering of ant idepressants and 
stimulants. Ho rmonal contraceptives are not excluded.
Parti cipants may  receive the COVID -19 vaccinat ion; however, vaccinat ions  
before checkin at any visit will not be allowed. Sites should document the vaccinat ion dosing on 
the concomitant medication pag e.
Meals and dietary  restricti ons are di scussed in Sectio n5.3.1 .
Table 6.b
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 53of 115
Protocol 17Aug 2022
CONFIDENTIALTable 6.b
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 56of 115
Protocol 17Aug 2022
CONFIDENTIALNote: All attempts should be made to determine the underlying reason for the withdrawal 
and, where possible, the pri mary  underlying reason shoul d be recorded (for example, 
withdrawal due to an AE shoul d not be recorded i n the “vo luntary withdrawal” category ). 
Similarly, lack of efficacy should not be recorded in the “vo luntary withdrawal” category .
Study terminated by s ponsor. 
The sponsor, inst itutional review board (IRB), or independent ethics committee (IEC), or 
regul atory  agency terminates the study .
Other (specify).
Note: The specific reasons should be recorded in the “specify” field of the eCRF, including 
unavo idable circumstances such as the COVID -19 pandemic
7.2 Participant Discontinuation/Withdrawal from the Study 
A participant may withdraw fro m the study  at any  time and for any  reason wi thout prej udice to 
their future m edical care by the physician or at the inst itution, or m ay be wi thdrawn at any  time 
at the discretion of the invest igator or sponsor (eg, in the interest of participant safet y). The 
investigator is encouraged to discuss withdrawal of a participant with the medical mo nitor when 
possible. 
The invest igator m ay discontinue a parti cipant’s study  parti cipat ion at any  time during the study  
when the participant meets the study  terminat ion criteria described in Sect ion7.1.
At the time of discont inuing from the study , if possible, an early terminat ion visit should be 
conducted, as shown in the SOA (see
 Table 1.a). The primary criterion for terminat ion must be 
recorded by  the invest igator. See SOA for data to be co llected at the time of study  
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be completed. 
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent.
Parti cipants who di scontinue or wi thdraw may  be repl aced.
7.3 Lost to Follow -up
The parti cipant may  be lost to follow -up as defined in Sect ion7.1.
8. Study Assessments and Procedures 
Written or electronic informed consent must be obtained (signed and dated ) before study  
assessments and procedures can be performed, as described in Section 10.1.3 .
The fo llowing sect ions describe the study  procedures and data to be collected at planned t ime 
points per the SOA (see Table 1.a). Protocol waivers or exempt ions are not allowed. 
Repeat or unscheduled samples m ay be taken for safet y reasons or due to technica lissues with 
the sam ples. Whenever possible, the same person should perform each assessment.
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 59of 115
Protocol 17Aug 2022
CONFIDENTIAL8.1.4.2. HLA Genotyping 
HLA DQ B1*06:02 ty ping will be obtained from participants during screening unless previous 
HLA results are reviewed and accepted by  the PI and incl uded in the source study  
docum entati on. Alm ost all  patients with NT1 who experience cataplectic attacks have this HL A 
genoty pe (heterozy gous or hom ozygous expressio n), which has been found to correlate with low 
OX concentrations in the CSF. Therefore, this genoty pe is viewed as a surrogate bio marker in 
the right clinical  setti ng. 
8.1.5. Administrative Procedures (Contingency Measures for Unavoidable 
Circumstances)
In unavo idable circumstances (eg, a widespread disease outbreak or natural disaster) that impact 
the study  site’s abili ty to conduct study  procedures according to the SOA (see Table 1.a), 
contingency measures may be implemented. In acknowledgement of study  site, hospi tal, local, 
state, and national restrict ions established in response to circumstances like COVID -19,the 
following measures are being taken for the current study :
For parti cipants active in the study , all attem pts shoul d be m ade to perform  the assessments 
with the parti cipant present at the site using the visit windows. Exceptions may  be granted for 
alternative approaches to study  procedures and data collect ion through approval by the 
sponsor or designee. Such instances must be documented in the study  records and m ay 
include the fo llowing:
–Sites im pacted by  the COVID -19 pandemic or similar unavo idable cir cumstances, m ust 
contact the sponsor or designee to discuss individual participant and site circumstances to 
obtain approval for use of alternat ive approaches to study  procedures and data collect ion 
due to COVID -19 or other unavo idable circumstances.
–Sitesmay seek approval fro m the sponsor or designee to continue part icipants in the 
study  despi te departures from  the SOA (see Table 1.a). The PI is expected to eval uate the 
impact to the safet y of the study  parti cipants and site personnel for participants to 
continue. In evaluat ing such requests, the sponsor or designee will give the highest 
priori ty to the safet y and welfare of the participants. Participants must be willing and able 
to con tinue taking study  drug and rem ain com pliant wi th the protocol . 
–Alternat ive methods for conducting participant visits (eg , video conferencing, telephone 
visits, or in -home study  visits conducted by  study  site personnel  or desi gnated m edical 
personnel, contingent upon local regulat ions) may be used per approval by  the sponsor or 
designee: 
Under these circumstances, collect ion of certain study  assessments may  be omi tted 
and visit windows may be extended. 
When approval is given for a participant to miss an in -person study  visit, a study  site 
physician will speak directly wit h the parti cipant by  telephone or other m edium  (eg, a 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 60of 115
Protocol 17Aug 2022
CONFIDENTIALcomputer -based video communication) during each visit window to assess participant 
safet y and overall clinical status. 
The study  site physician or other qualified site personnel should conduct the 
following assessments within specified -visit window ti me frames: AE assessments, 
docum entati on of  concomi tant m edicati on, administrati on of  C-SSRS (at applicable 
visits), and an assessment of clinical symptoms. 
For thi s study , hom e nurses or other qualified clinical personnel may  be depl oyed at 
the request o f the site, when appropri ate. Advance approval fro m the sponsor or 
designee should be obtained.
Other study  assessments may be co llected using an alternative method as feasible and 
may invo lve audio or video recording where allowed by local regulat ion. Thi s will  be 
docum ented in the study  records.
Vaccinat ions  before check -in at any visit will not be allowed. 
Parti cipants may  choose to get a COVID -19 vaccine at any other time during this 
study . 
In some instances, sites may need to split vis its or sites may only be able to perform a 
few procedures on site and so me procedures may need to be performed remotely. 
Sites shoul d inform  sponsor or desi gnee when this occurs.
Sites m ay seek approval  to extend a visit window to conduct an on -site visi t.
Assessments that cannot be completed during the protocol -specified window or 
within the visit window granted by  the sponsor or designee will be considered 
missing data and such departures will be recorded in the study  records. 
There will be no interval l onger than approximately  2weeks between successive 
visits at whi ch clinical laboratory  tests are performed and vital signs are measured. 
Shoul d the peri od of  4weeks be met for a particular participant, the site should 
contact the sponsor or designee to discuss withdrawal of the participant. Local 
laboratories may  be used if necessary .
–Study  site personnel  may dispense addit ional study drug to participants at a visit to allow 
for potenti ally longer intervals between visit s than ori ginally planned per proto col, or 
study  drug m ay be supplied to participants via delivery  by si te personnel or by  couri er.
–Early terminat ion visits should be performed in person. When it is not possible for the 
participant to com e to the study  site and the protocol -specified visit window cannot be 
extended further, the preferred alternat ive for the early  terminat ion visit is for qualified 
study  site personnel or desi gnated clinical personnel to go to the participant’s residence 
and conduct the protocol -specified procedures in that l ocati on. Assessments collected at a 
participant’s residence should comply with applicable local regulat ions. If neit her option 
is available wit h sponsor or designee approval, sites may conduct early terminat ion 
procedures remotely as is feasible.
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 69of 115
Protocol 17Aug 2022
CONFIDENTIALThe invest igator and any qualified designees are responsible for collect ing, detecting, 
docum enting, and recording events that meet the definit ion of an AE or SAE. They  remain 
responsible for fo llow-up of  these events (see Section 10.3.4). 
8.3.8.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs will be co llected fro m the signing of the ICF until final fo llow
-up visi t or roll over into 
the LTE at the time points specified in the SOA (see Table 1.a). 
All SAEs will be recorded and reported to the sponsor or designee immediately. Under no 
circumstance shoul d this exceed 24 hours. The investigator will also submit any  updated SAE 
data within 24 hours of it being available.
Invest igators are not obligated to actively seek info rmation on AEs or SAEs after conclusio n of 
the study  parti cipat ion. However, if the invest igator learns of any SAE, including a death, at any 
time after a partici pant has been discharged from the study , and he/she considers the event to be 
reasonably  related to the study  intervent ion or study participat ion, the invest igator must promptly 
notify the sponsor via the reporting method described in Section 10.3.4.6 .
8.3.8.2. Method of Detecting AEs and SAEs
At each study  visit specified in the SOA, participants will be quest ioned in a general way  to 
ascertain if AEs have occurred since the previous visit. Open -ended and nonleading verbal 
questioning of the participant is the preferred method to inquire about AE occurrences wit hout 
introducing bias. Participants may report AEs occurring at any  time during the study .
8.3.8.3. Follow -up of AEs and S AEs 
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All participants experiencing AEs, whether considered associated 
with the use of the study  drug or not, will be documen ted in the AE page of the eCRF. 
All AEs must be monitored until the end of the study  or until  the event resolves, stabilizes, is 
otherwi se explained, or the participant is lost to follow- up as defined in Sect ion7.3. 
SAEs m ust be m onitored until  resol ution, stabilizatio n, the event is otherwise explained, or the 
participant is l ost to foll ow-up. 
Inform ation to be documented for each event is define d in Sect ion10.3.4 .
Further informat ion on fo llow-up procedures i s provi ded in Sect ion10.3. 
8.3.8.4. Regulatory Reporting Requirements for SAEs 
Prom pt notificat ion by the invest igator to the sponsor of an SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies toward the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et. The sponsor has a legal responsibilit y to notify  
both the l ocal regulatory  authori ty and other regul atory  agencies about the safet y of a study  
intervent ion under clinical i nvesti gation. The sponsor will co mply with country -specific 
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 76of 115
Protocol 17Aug 2022
CONFIDENTIAL10. Supporting Documentation and Operational Considerations 
10.1 Regulatory, Ethical, and Study Oversight Considerations 
10.1.1. Regulatory and Ethical Considerations 
This study  will be conducted wi th the highest respect for the individual participants according to 
the ethi cal principles that have their origin in the Declarat ion of Helsinki, and the ICH 
Harm onised Tri partite Guideline for GCP. 
The study  sponsor and any third party  to whom  aspects of the study  management or m onitoring 
have been delegated will undertake their assigned roles for this study  in compliance wit h all 
applicable industry  regul ations, current ICH GCP Guidelines, as well as all applicable nat ional
and local laws and regulat ions.
10.1.2. Financial Disclosure 
Takeda is funding this study  and will make payments to the study  site for the conduct of the 
study  (and, if applicable, investigators and/or other study  staff), as specified in the Clinical Study  
Site Agreem ent(s).
Regulatory  authori ties including the Food and Drug Administration require Takeda to submit 
disclosures of invest igators’ and subinvest igators’ financial interests and arrangements. For this 
reason, Takeda will provide the investigators and sub -invest igators with a form for the disclo sure 
of their financial arrangements during the course of the st udy and f or 1 y ear after the complet ion 
of the study . 
The financial disclosure form must be signed by each invest igator and sub -investigator before 
the study  starts at thei r study  site. Any potenti al conflicts of interest that are not covered by  this 
formshoul d be discl osed separately to Takeda before the start of the study  at thei r site.
Specific financial arrangements requiring disclosure would include any arrangement whereby the 
outcom e of the study  coul d be influenced by  the value of the compensat ion for conducting the 
study , or other payments the invest igator received fro m the sponsor. Examples include: any 
significant payments from the sponsor or subsidiaries such as a grant to fund ongoing research, 
compensat ion in the form of equipment, retainer fo r ongoing consultat ion, or honoraria; any 
propri etary  interest in study  intervent ion; and any significant equit y interest in the sponsor or 
subsidiaries as defined in 21 Code of Federal Regulat ions 54 2(b) (1998). 
The invest igator and sub -invest igator sho uld declare all inst itutional affiliat ions on the curricula 
vitae that they  provi ded to sponsor before the start of the study .
10.1.3. Informed Consent Process 
It is the responsibilit y of the invest igator to obtain written and/or electronic informed consent 
from all parti cipants before any study -related procedures including screening assessments. All 
eConsent documentation must be in accordance with applicable regulat ions and GCP:
The parti cipants m ust receive an explanation of what the study  involves, including b ut not 
limited to: the object ives, potential benefits and risk, inconveniences, and the participant’s rights 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 77of 115
Protocol 17Aug 2022
CONFIDENTIALand responsibilit ies. eConsent provides the same informat ion as written consent forms, but in an 
electroni c format that m ay include mul timedia components. eConsent does not replace the 
important discussio n between the study  parti cipant and site staff or invest igator. Regardless of 
the consent format –written or eConsent –the investigational site is responsible for the 
consent ing process.
After the participant has received and read (or been read) the participant informat ion, they will 
be requested to sign and date the informed eConsent form or a certified translat ion if applicable. 
Persons consent ing via eConsent, where available, will electronically sign consent forms. (Paper 
consent forms will be used instead, if required by local regulations.)
A copy  of the inform ed eConsent documentation (ie, a complete set of participant informat ion 
sheets and fully  executed si gnature pages) must be provided to t he participant, as applicable. 
This document may require translat ion into the l ocal language. Si gned eConsent forms must 
remain in each participant’s study  file at the si te (ei ther in thei r original, si gned paper form  or as 
a certified copy  if applicable f or electroni c signature) and m ust be available for verificat ion at 
any time.
The PI provides the sponsor with a copy  of the eConsent form that was reviewed by the IRB/EC 
and received their favorable opinio n/approval. A copy  of the IRB/EC’s written favorabl e 
opinio n/approval o f these documents must be provided to the sponsor before the start of the 
study  unless i t is agreed to and documented (abiding by regulatory  guidelines and nat ional 
provi sions) before study  start that another party  is responsible for th is act ion. Addit ionally , if the 
IRB/IEC requires modificat ion of the sample participant informat ion and eConsent document 
provi ded by the sponsor, the documentation supporting this requirement must be provided to the 
sponsor.
10.1.4. Data Protection
The confident iality of records that may  be able to ident ify part icipants will be protected in 
accordance with applicable laws, regulat ions, and guidelines.
After parti cipants have consented to take part in the study , the sponsor and/or its representatives 
reviews their source documents and data collected during the study . These records and data may , 
in addition, be reviewed by  others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties wit h whom the sponsor may devel op, regi ster, or 
market TAK -861; national or l ocal regul atory  authori ties; and the IRB(s)/IEC(s) which gave 
approval  for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in acc ordance wi th applicable laws, regulations, and 
guidelines to m aintain the confident iality of parti cipants’ ident ities. Participants are assigned a 
unique identifying number; however, their init ials and date of birth may  also be collected, if 
permitted unde r local laws governing privacy. 
The results of studies containing participants’ unique ident ifying number, relevant source 
docum ents, and possibly  initials and dates of birth, where allowed per local law, may be 
transferred to, and used in, other countrie s that m ay not aff ord the same l evel of protecti on that 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 78of 115
Protocol 17Aug 2022
CONFIDENTIALapplies within the countries where this study  is conducted. The purpose of any  such transfer 
woul d incl ude: to support regul atory  submissi ons, to conduct new data analyses to publish or 
present the st udy results, or to answer quest ions asked by regulatory  or heal th authori ties. 
The sponsor will assign each participant a unique ident ifier. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant names 
or any  informat ion that would make the participant identifiable will not be transferred.
The invest igator must inform the participant that their personal study -related data will be 
used by the sponsor in accordance wit h local data protecti on law.The level o f disclosure 
must al so be explained to the participant who will be required to give consent for their data to 
be used as described in the ICF. 
The invest igator must inform the participant that their source documents may be examined 
by Clinical Quali ty Assurance auditors or other authorized personnel appo inted by  the 
sponsor, by  appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
All United States -based sites and laboratories or entit ies providing support for this study, must, 
where applicable, comply with the Healt h Insurance Portabilit y and Accountabilit y Act of 1996. 
A site that is not a covered ent ity as defined by Health Insurance Portabilit y and Accountabilit y 
Act m ust provi de docum entati on of  this fact to the sponso r or desi gnee.
10.1.4.1. Notice Regarding the Use and Transfer of the Investigator’s Personal 
Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and telephone number, and other personally ident ifiabl e informat ion such as educat ion 
and professio nal details, payment -related details (if applicable), ident ity information (eg, medical 
registrati on number) and informat ion relating to his or her interactions and act ivities wit h or 
involving Takeda. In addit ion, invest igator’s personal informat ion may be transferred to other 
parties located in countri es throughout the world including the fo llowing:
Takeda, its affiliates, and their licensing partners.
Business partners assist ing Takeda, its affiliates, and the ir licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda 
and these other parties for research purposes including the following:
–Assessm ent of  the sui tabilit y of invest igator for the study  and/or other clinical studies.
–Management, monitoring, inspect ion, and audit of the study .
–Analysis, review, and verificat ion of the study  results.
–Safety reporti ng and pharmacovigilance relat ing to the study .
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 79of 115
Protocol 17Aug 2022
CONFIDENTIAL–Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
–Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to other medications used in other clinical studies that may 
contain the same chemical compound present in the study  drug.
–Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
–Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
–Archiving and audit of study  records.
–Posting investigator site contact informat ion, study details and results on publicly 
accessible clinical trial registries, databases, and websites.
In addit ion, where required by  lawor industry  codes of practi ce, Takeda and/or its affiliates may 
have to report or publicly disclose any payments or transfers of value made in connect ion with 
the study  by or on behalf o f Takeda and/or its affiliates or their service providers to the 
investigator or thei r inst itution.
The l egal basis on which Takeda and its affiliates will process the invest igator’s personal 
inform ation for the above purposes are to comply  with a legal obligati on; or to perform  any 
contract in place wit h the invest igator ( if applicable); or to meet the legit imate research, 
scientific and business interests of Takeda and its affiliates, including ensuring the proper 
perform ance of thi s study  to the applicable standards, appropriate reporting of study  resul ts and 
archiving of study -related records and informat ion, and further development and registration of 
the study  drug or other compounds. The invest igator may not be able to opt- out of thi s 
processing, or the invest igator’s choice to opt -out may impact his or her abilit y to continue to 
participate in this study  and/or future studies invo lving Takeda and/or its affiliates. 
Takeda and its affiliates will maintain physical, administrative and technical safeguards to 
protect the invest igator’s personal information from lo ss, mis use, unauthori zed access, 
disclosure, al terati on or destruction. The invest igator’s personal informat ion may be transferred 
to other countries that do not have data protection laws that offer the same level of protection as 
data protecti on laws in invest igator’s own country .
However, where invest igator’s personal information is transferred to Takeda affiliates, licensing 
partners, business partners or service providers in such countries, Takeda will ensure that all 
adequate safeguards are in place and that all applicable laws and regulat ions are com plied wi th in 
connection wit h such transfers.
The invest igator’s personal informat ion will only be stored as long as necessary  for the purposes 
for which i t was collected parti cipant to l ocal laws and regulations and legit imate scient ific, 
research and business needs.
Individuals located in the European Economic Area and in certain other countries have certain 
data parti cipant ri ghts which m ay be parti cipant to limitations and/or restrict ions. These rights 
include the right to: (i ) request access to and rectification or erasure of their personal data; (ii) 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 80of 115
Protocol 17Aug 2022
CONFIDENTIALobtain restrict ion of processing or to object to processing of their personal data; (iii) the right to 
data portabilit y; and (iv) obtain addit ional informatio n regarding the safeguards Takeda has in 
place for cross -border transfers of their personal data. If the invest igator wishes to exercise one 
of these ri ghts, the invest igator may use the contact information below. 
Individuals located in the European Economic Area and in certain other countries may also have 
the right to l odge a com plaint about the processing of their personal data with their local data 
protecti on authori ty.
The invest igator can contact Takeda to exercise his or her rights, make inquiries or submit 
complaints concerning Takeda’s processing of his or her personal information. Takeda will take 
appropriate steps to address requests, inquiries and complaints. Takeda will respond to such 
requests within thirt y (30) business days.
Contact Details:
Mailing Address: Attn: Data Protection Officer, Legal Department, Takeda Pharmaceut icals 
International AG, Thurgauerstrasse 130, CH -8152 Glattpark -Opfikon (Zurich), Switzerland.
Email Address: dataprivacy@takeda.com
The invest igator acknowledges and authori zes the use of his or her personal information by  
Takeda and other parties for the purposes described above.
10.1.5. Committees Structure 
10.1.5.1. IRB and/or IEC Approval
IRBs/IECs must be const ituted according to the applicable state and federal/local requi rements of 
each parti cipat ing region. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRBs/IECs . If any member of the IRBs/IECs
has di rect parti cipat ion in this study , written notification regarding hi s or her abstinence fro m 
voting must also be obtained. 
Those Americas sites unwilling to provide names and tit les of all members due to privacy  and 
conflict of interest concerns should instead provide a Federalwide Assurance Number or 
comparable number as signed by  the Department of Heal th and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRBs/ 
IECs for the protocol ’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, participant recrui tment materi als and/or advertisements and other documents required 
by all applicable laws and regulations, must be submitted to a central or local IRBs/IECs for
approval . 
The IRB’s/IEC’s written approval of the protocol and participant I CF must be obtained and 
submitted to the sponsor or designee before commencement of the study  (ie, before shipment of 
the sponsor -supplied drug or study specific screening act ivity).
The IRBs/IECs approval  must refer to the study  by exact protocol tit le, number, and versio n 
date; i dentify versio ns of other documents (eg, ICF) reviewed; and state the approval date. If 
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 82of 115
Protocol 17Aug 2022
CONFIDENTIALMoni toring details describing strategy , including definit ion of study  critical data i tems and 
processes (eg, r isk-based init iatives in operations and qualit y such as ri sk management and 
mitigation strategies and analyt ical risk- based mo nitoring), m ethods, responsibilit ies, and 
requi rements, including handling of nonco mpliance i ssues and m onitoring techniques (cent ral, 
remote, or on -site monitoring) are provided in the mo nitoring plan/contracts.
Visits to si tes are conducted by  representatives of the study  sponsor and/or the company  
organi zing/managing the research on behalf of the sponsor to inspect study  data, par ticipants’ 
source documents, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may addit ionally  be 
reviewed by  audi tors or by  regul atory  authori ties.
The sponsor or designee is responsible for the data management of this study , including qualit y 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, contract 
research organizat ions [CROs]).
Records and documents, inclu ding signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for 2 years after study  com pletion unless local regulat ions or 
institutional policies requi re a l onger retenti on period. No records may be destroy ed during the 
retenti on peri od wi thout the wri tten approval  of the sponsor. No records may  be transferred to 
another location or party  without wri tten notificat ion to the sponsor.
10.1.7.1. Protocol Deviations
The invest igator should not deviate fro m the protocol , except where nec essary  to eliminate an 
immediate hazard to study  parti cipants. Shoul d other unexpected ci rcumstances arise that will 
requi re deviat ion from protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB or IEC, as requ ired) to determine the appropriate course of act ion. 
There will be no exempt ions (a prospectively approved deviat ion) fro m the inclusion or 
exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the parti cipant, or confound interpretation of primary  study  
assessment.
10.1.7.2. Study -Site Monitoring Visits 
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and the study site head guarantee access to source documents by the sponsor or 
its designee (CRO and/or auditor) and by  the IRB/IEC or any  other heal th authori ty governing 
the study , per l ocal/regional regul ation.
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 84of 115
Protocol 17Aug 2022
CONFIDENTIALauthori ties. Data collect ion procedures will be discussed with the site at the site init iation visit 
and/or at the invest igator’s meet ing. eCRFs must be completed in English . 
The invest igator has full responsibilit y for the accuracy and authent icity of all data entered on the 
eCRFs. Details are provided in Section 10.1.11.2 .
A study  monitor from the sponsor or i ts de signee will  visit each si te in accordance wi th the 
monitoring plan and review the eCRF data against the source data for completeness and 
accuracy . Auditors, IRB/IEC members, or regul atory  inspectors may also check the eCRF entries 
against the source docume nts.
Discrepancies between source data and data entered on the eCRF will be addressed by qualified 
site personnel. When a data discrepancy warrants correction, the correction will be made by  
authori zed si te personnel . 
After the lock of the study  database, any change of, m odificati on of  or addi tion to the data on the 
eCRFs should be made by the invest igator with use of change and modificat ion records of the 
eCRFs. 
Correcti ons to eCRFs are recorded in an audit trail that captures the old information, the ne w 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and the reason for change. Reasons for significant corrections should also be included. The PI 
must review the data change for completeness and accuracy , and m ust si gn, or si gn and seal, and 
date. In  the eCRF Data Clarification Form will be provided by the sponsor or designee.
After complet ion of the entry  process, com puter l ogic checks will be run to identify items, such 
as inconsistent dates, missing data, and questionable values. 
The completed eCRFs are the sole property  of the sponsor and should not be made available in 
anyform to thi rd parti es, except for authorized representatives of appropriate governmental 
healt h or regul atory  authori ties, wi thout wri tten permissio n of the sponsor. 
All data will have separate source documentation; no data will be recorded directly onto the 
eCRF.
10.1.8.2. Documentation and Retention of Records
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF. Source documents provide evidence for the existence of the 
participant and substant iatethe integri ty of the data collected. Source documents are filed at the 
investigator’s site. A definit ion of what constitutes source data and its origin can be found in 
Secti on10.1.8.4 .
Data entered in the eCRF that are transcribed from source documents must be consistent with the 
source documents or the discrepancies must be explained. The invest igator may need to request 
previous source documents or transfer records, depending on the study . Also, current source 
docum ents m ust be available.
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 85of 115
Protocol 17Aug 2022
CONFIDENTIALStudy  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and v erifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regulatory requirements. A ri sk-based monitoring 
approach will be used.
10.1.8.3. Data Handling
The full details o f procedures for data handling will be documented in the Data Management 
Plan. AEs, m edical history , and concurrent medical condit ions will be coded using the Med DRA. 
Drugs will be coded using the World Heal th Organizat ion Drug Di ctionary/Japanese Drug 
Dictionary.
Data are to be entered into a clinical database as specified in the data management plan or 
similar. Qualit y control  and data validat ion procedures are a pplied to ensure the validit y and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarificati on using com puterized and m anual procedures. Data queries requiring clarificat ion are 
tobe communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
10.1.8.4. Record Retention
The fo llowing procedure applies to countries other than .
The invest igator agrees to keep the records stipulated in Section 10.1.8.1 and those documents 
that include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing participants, source documents, temporary media such as thermal sensit ive paper, 
source worksheets, all original signed and dated informed eConsent forms (including consent to 
use di gital tools and applicat ions, if applicable), participant authorizat ion forms regarding the use 
of personal  health informat ion (if separate from the informed eConsent forms), query  
responses/electronic copy  of eCRFs, including the audit trail, and detailed records of drug 
disposi tion to enable evaluat ions or audits fro m regul atory  authori ties, the sponsor or its 
designees. Any source documentation printed on degradable thermal sensit ive paper should be 
photocopi ed by  the si te and filed wi th the ori ginal in the parti cipant’s chart to ensure long -term 
legibilit y. Furtherm ore, ICH E6(R2) Secti on5.5.11 requires the invest igator to retain essent ial 
docum ents specified in ICH E6(R2) (Section 8) until  at least 2 years after the last approval of a 
market ing application for a specified drug indicat ion being investigated or, if an applicat ion is 
not approved, until at least 2 years after the invest igation is discont inued and regulatory 
authori ties are notified. In addit ion, ICH E6(R2) Section 5.5.11 states that the study  records
shoul d be retained unt il an amount of time specified by applicable regulatory requirements or for 
a time specified in the study  site agreement between the investigator and sponsor.
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 86of 115
Protocol 17Aug 2022
CONFIDENTIALRefer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of 
any such documents.
The fo llowing procedure applies to sites in  only:
The invest igator and the head o f the study  site agree to keep the reco rds stipulated in 
Secti on10.1.8.1 and those documents that include (but are not limit ed to) the study -specific 
docum ents, the i dentificat ion log ofall part icipating participants, source documents, temporary  
media such as thermal sensit ive paper, source worksheets, all original signed and dated informed 
eConsent forms, participant authorizat ion forms regarding the use of personal healt h informat ion 
(if separate from the informed eConsent forms), telemedicine records, and query responses/ 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its desi gnees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the participant’s chart to ensure long -term legibilit y. The 
investigator and the head of the institut ion are required to retain essent ial relevant docum ents 
until the day specified as 1) or 2) below, whichever comes later. However, if the sponsor 
requests a longer time period for retention, the head of the institution should discuss how long 
and how to re tain those documents with the sponsor.
1.Theday on which market ing approval of the study  drug i s obtained (or the day 3 years after 
the date of notificat ion in the case that the invest igation is discont inued).
2.Theday 3 years after the date of early  termina tion or com pletion of the study . 
In addit ion, the invest igator and the head of the institution should retain the essent ial relevant 
docum ents unt il the receipt of a sponsor -issued notificat ion to state the retention is no longer 
requi red. 
When proceeding to the l ocal postm arket ing study , the investigator and the head of the 
institution are requi red to retain essent ial relevant docum ents unt il the end of re -examinat ion or 
re-evaluat ion, whichever comes later. However, if the sponsor requests a longer time period for 
retenti on, the head of the inst itution shoul d discuss how l ong and how to retain those documents 
with the sponsor. 
10.1.9. Study and Site Start and Closure
10.1.9.1. First Act of Recruitment 
The first act of recruitment is the first site open.
For clinical tria l disclosure purposes, the study  start date i s the date when the first participant 
signed the ICF.
10.1.9.2. Study/Site Termination 
The sponsor may suspend or terminate the study , or part of the study , at any  time for any  reason. 
The sponsor reserves the right to close the study  site at i ts sole di screti on. Study  sites will be 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 87of 115
Protocol 17Aug 2022
CONFIDENTIALclosed on study  com pletion. A study  site is considered cl osed when all required documents and 
study  supplies have been collected and a study -site closure visit has been performed.
If the study  is suspended or terminated, the sponsor will ensure that applicable sites, regulatory  
agencies, CRO(s), and IRBs/IECs are notified as appropriate and as specified in applicable 
regul atory  requi rements. Addi tionally, the discontinuat ion of a registered clinical study  which 
has been posted to a designated public website will be updated accordingly. Further, the 
investigator sha ll pro mptly inform  the parti cipants and should assure appropriate participant 
therapy  and/or follow -up. If the study  is terminated, the sponsor will make an end of study  
declaration to the relevant competent authorit y as requi red by Article 10( e) of Direc tive 
2001/20/EC and the European Union (EU) Clinical Trial Regulation. 
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
For study  terminat ion or suspensio n:
–Discontinuati on of  further study  intervent ion developm ent.
–New informat ion or other evaluat ion regarding the safet y or eff icacy  of the study  drug 
that indicates a change in the known benefit -risk profile for TAK -861 such that the 
benefit -risk is no l onger acceptable for participants participat ing in the study .
–The DMC reco mmends that the study should be suspended or terminate d. 
–A finding (eg, PK, PD) from another nonclinical or clinical study  using the study  drug 
leads to the study  being stopped for reasons unrelated to safet y.
– Data from drug(s) of the same class or methodology (or methodologies) used in this study 
beco me available and result in the study  being stopped for reasons unrelated to safet y.
–Significant vio lation of GCP that compromises the abilit y to achieve the primary study  
objectives or compromises participant safet y.
–The sponsor terminates or suspends the stu dy at any t ime for any  other clinical  or 
administrative reasons, eg, slow enrollment.
For si te terminati on or suspensi on:
–Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor’s pr ocedures, or GCP guidelines .
–Inadequate or no recruit ment (evaluated after a reasonable amount of time) of participants 
by the investigator .
–Total  number of participants enro lled earlier than expected .
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 89of 115
Protocol 17Aug 2022
CONFIDENTIAL10.1.11. Responsibilities of the Sponsor and the Investigator
10.1.11.1. Sponsor Responsibilities
The sponsor is responsible for designing and performing the study  in accordance wit h ICH GCP 
Guideline E6, EU Direct ive 2001/20/E C, other applicable regulatory  requi rements and 
guidelines, and rul es considering the rights, safet y, and well -being of human participants.
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
clinical supplie r list in the study  manual . The identified vendors will perform these act ivities 
either in full or in partnership with the sponsor.
The sponsor ensures that local regulatory  authori ty requi rements are met before the start of the 
study . The sponsor (or desi gnee) is responsible for the preparation, submissio n, and confirmat ion 
of recei pt of  any regulatory  authori ty approvals requi red before rel ease of study  intervent ion for 
shipment to the site.
Takeda is funding the study  and is responsible for collect ing financial  discl osure inform ation 
from invest igators and sub -invest igators, for submissio n to regulatory  authori ties 
(Secti on10.1.2 ).
The sponsor/ de signee will supply the fo llowing:
Docum entati on requi red for the study  conduct, including but not limited to the study  
protocol , IB, study  operati ons m anual, other study  conduct/ m anagement docum ents and 
sample informed consent.
Access to the IEC/IRB -appro ved versio n via an eConsent plat form (Secti on10.1.3 ).
eCRFs, data management, and site monitoring (Section 10.1.7), including reconciliat ion with 
source documents (Section 10.1.8).
The sponsor is responsible for protecting the confident iality of parti cipants’ data 
(Secti on10.1.4 ).
The sponsor will fulfill its role in forming and managing any  special committees as described in 
Secti on10.1.5 .
The sponsor is responsible for the reporting of data to regulators and the public disclosure of data 
as described in (Section 10.1.6 ). The sponsor is also responsible for maintaining a publication 
policy  (Secti on10.1.10 ) that bal ances the protecti on of  parti cipants’ data (Section 10.1.4 ), public 
disclosure requi rements (Secti on10.1.6), and industry  publicati on standards.
The sponsor and/or designee selects sites and performs study  site start and cl osure acti vities 
(Secti on10.1.9 ).
The sponsor will supply insurance for each participant in the study  in accordance with the 
regul ations applicable to the site where the participant is participat ing. If a local underwriter is 
requi red, then the sponsor or sponsor’s designee will obtain clinical study  insurance against the 
risk of injury to study  partici pants. Refer to the study  site agreement regarding the sponsor’s 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 90of 115
Protocol 17Aug 2022
CONFIDENTIALpolicy  on parti cipant com pensat ion and treatment for injury . If the invest igator has quest ions 
regarding this po licy, he or she should contact the sponsor or spons or’s desi gnee.
10.1.11.2. Investigator Responsibilities 
The invest igator must perform the study in accordance wit h ICH GCP Guideline E6, EU 
Directive 2001/20/EC, other applicable regulatory requirements and guidelines, and rules 
considering the rights, safet y, and well -being of human participants.
The invest igator and any sub -investigators must adhere to this protocol, with major 
responsibilit ies summarized below.
It is the invest igator’s responsibilit y to ensure that adequate time, resources, and appropriately  
trained personnel are available before committing to participate in this study . 
Each of the investigators will maintain a list of appropriately qualified pe rsons to whom  they  
have delegated significant study -related tasks. Investi gators will  provide thei r own curricula vitae 
and those of their sub -investigators to the study  sponsor (or desi gnee) before starting the study , 
and will, on request of the sponsor, provide addit ional docum entati on of  any licenses and 
certifications necessary  to dem onstrate these qualificat ions. 
The invest igator and sub -invest igators are required to disclo se any  potenti al conflicts of interest 
during or within 1 year after the end of the study  (Secti on10.1.2 ).
The invest igator will eit her conduct the activit ies in the protocol personally or provide guidance 
and supervisio n to the staff who assist. The investigator will provide necessary informat ion about 
the protocol and the responsibilit ies of individual person nel. The invest igator will ensure that 
study -related procedures, including study  specific (nonroutine/nonstandard panel) screening 
assessments are NOT performed on potential participants, before the receipt of written approval 
from relevant governing bodie s/authori ties.
The invest igator will co mmunicate with the local IRB/IEC to ensure that it has performed init ial 
review, continuing review, and approval of the protocol. The investigator will prompt ly report all 
changes in research act ivity and all anticipa ted ri sks to parti cipants to the IRB/IEC. The 
investigator will report on the progress of the study  to the IRB/IEC at l east once per y ear and will 
issue a final report within 3 mo nths of study  com pletion.
The invest igator will obtain valid informed consent from each parti cipant in the study  
(Secti on10.1.3 ). The invest igator is responsible for screening participants and for enrolling only 
those parti cipants who have met protocol eligibilit y criteria. If a potential research part icipant has 
a primary  care physician, the invest igator should, with the participant’s consent, inform them o f 
the participant’s part icipation in the study. 
The invest igator must protect the participant’s privacy rights as described in Sect ion10.1.4 and 
explain to the participant how their data will be used. The publication policy  also encom passes 
some el ements designed to protect individual part icipants’ data (Section 10.1.10 ).
The invest igator will prepare and maintain adequate cas e histori es of  all participants entered into 
the study , including hospital records and laboratory  resul ts (Secti on10.1.8 ). The invest igator will 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 91of 115
Protocol 17Aug 2022
CONFIDENTIALbe responsible for reviewing data, reports, and interlaboratory /reader standardizat ion methods (if 
applicable). The invest igator or the invest igator’s designee (ie, authorized site personnel, as 
stated in the site delegat ion log) must enter data from the sour ce documents (Section 10.1.8 ) into 
the eCRF wit h gui dance from  the study  CRF Compl etion Guidelines or similar. The invest igator 
will prepare correct and complete eCRFs for all participants and/or will check and confirm the 
contents of eCRFs entered by  the subinvesti gator or transcribed fro m the source data. The 
investigator will electronically sign the eCRFs as a means of attesting to the integrit y of the data 
and will submit them to the sponsor. Furthermore, the invest igator must retain full responsibilit y 
for the accuracy  and authent icity of all data entered on the eCRFs. The invest igator will maintain 
current records of the receipt, administration, a nd di sposi tion of  sponsor -supplied drugs 
(Secti on10.1.7 ).
The invest igator will maintain these data for a minimum o f 2 years fo llowing notificat ionby the 
sponsor that all invest igations have been discontinued or that the regulatory authorit y has 
approved the market ing application. The invest igator should contact and receive written approval 
from the sponsor before disposing of any  such docum ents (Se ction10.1.8 ).
The invest igator will facilitate monitoring and auditing activit ies and will allow the regulatory  
authori ties to inspect and copy  GCP -specified essent ial documents.
The invest igator has overall responsibilit y for dispensing study  drug will  return all unused 
sponsor -supplied study intervention, containers, and other study materials to the sponsor on 
completing or leaving the study. If the invest igator suspends or terminates the study at their site, 
the invest igator will pro mptly inform  the sponsor and the IRBs/IECs and provide them with a 
detailed written explanat ion (Section 10.1.9 ). 
Upon study  com pletion, the invest igator will provide the sponsor, IRB/IEC, and regulatory  
agency  with final reports and summaries as required by (inter)nat ional regulat ions
10.1.11.2.1. PI/Coordinating Investigator
ThePI/coordinat ing invest igator will be required to review and sign the final clinical study report 
and by  doing so agrees that i t accurately  describes the resul ts of the study , in com pliance wi th 
Directive 2001/83/EC as amended by Direct ive 2003/63/EC an d ICH Guidance E3 (1995).
10.2 Clinical Laboratory Tests 
Table 10.a lists the tests that will be performed for each laboratory  specimen. These tests will be 
perform ed by  the central  laboratory .
Addit ional tests may be performed at any  time during the study  asdetermined necessary  by the 
investigator or required by  local regulati ons.
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 103of 115
Protocol 17Aug 2022
CONFIDENTIALbe sufficient to consider changes in the study  drug/sponsor supplied drug administration or in 
the overall conduct of the study . 
The study  site will  forward a copy  of all expedited reports to its IRB or IEC in accordance with 
local regulati ons.
10.4 Contraceptive and Barrier Guidance 
10.4.1. Definitions 
For the purposes of this study , reproductive status is defined as fo llows: 
Non-pregnant: Negative urine and/or serum β -hCG pregnancy  test resul t
Person who is not of childbearing potential:
–Prem enarchal and 1 of the fo llowing: 
Tanner stage 1.
Younger than 9 years of age.
–Surgically sterile for at least 6 weeks at screening (defined as having undergone one of 
the following procedures: hysterectomy , bilateral  tubal ligati on, bilateral  oophor ectomy 
or bilateral salpingectomy).
–Postmenopausal  at screening (defined as no m enses for 12 months wit hout an alternat ive 
medical cause). A high FSH level in the postmenopausal range (FSH >40 IU/L) may  be 
used to confirm a postmenopausal state in y ounger wom en (eg, those aged <45 y ears) or 
wom en who are not using hormonal contraception or hormonal replacement therapy . 
However, in the absence o f 12 m onths of amenorrhea, a single FSH measurement is 
insufficient.
Person who isof childbearing potential : after menarche and unt il beco ming post -
menopausal unless permanent ly sterile by  the defini tion above.
Male who isnot fertile : pre-pubert y OR post -puberty  but perm anent ly sterile by bilateral 
orchi dectomy . Sterilized males should be at least 1 year post –bilater al vasectomy  and have 
confirmed that they  have obtained docum entati on of  the absence of sperm in the ejaculate or 
have had bilateral orchidectomy .
Male who isfertile
: post puberty , unless permanently  sterile by  the defini tion above.
10.4.2. Contraception Guidance
In thi s study , the use of highly  effect ivecontraceptio n is generally required unless otherwise 
noted. In addit ion, contraceptive use should be consistent with local regulat ions regarding the use 
of contraceptive methods for participants in clinical stud ies.
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 104of 115
Protocol 17Aug 2022
CONFIDENTIALThe failure rates of contraceptives that are used consistent ly and correctly may differ in typical 
use. Therefore, when study  parti cipat ion requires any o f these methods of contraception to be 
used, participants must commit to using them:
Consistent lythroughout the requi red peri od.
Correctly , as described below and in any  labeling associ ated wi th the m ethod.
Contraception requirements depend in part on the reproductive status of the participant and the 
participant’s partner. 
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 105of 115
Protocol 17Aug 2022
CONFIDENTIALTable 10.b Acceptable Contraception Methods and Lactation Guidance for this Study
Highly Effective Contraceptives: Failure rate of <1% per year -when used consistently and correctly
User Dependent
Combined (estrogen and progestoge n containing) hormonal contraception associated with inhibition of 
ovulatio na,b
–Oral 
–Intravaginal 
–Transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulationa,b
–Oral 
–Injectable
Sexual abstinence c 
Low User Dependency
Implantable progestogen only hormonal contraception associated with inhibition of ovulationa,b
Intrauterine device 
Intrauterine hormone -releasing system 
Bilateral tubal occlusion
Vasectomy; vasectomized partner d,e
Measures Intended to Prevent Fetal and Neonatal Exposure via Sperm or Breastmilk
Participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each episode of penile penetration throughout the duration of the s tudy 
and for days after the last dose of study drug. 
a Hormonal contraceptives must be stabilized .
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. Therefore , participants using hormonal contraception to fulfill the requirement for highly 
effective contraception must also use a barrier method of contraception (eg, condom use) durin g the treatment period 
and for  after the last dose of study treatment (i.e., a total of ) .
c Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the e ntire period of risk associated with the study treatment. The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
d A vasectomy is a highly effective cont raceptive method only if the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used.
e For participants of childbearing ability, having a vasectomized partner is a highly effective contraception m ethod 
provided that the partner is the participant’s sole partner and that the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used.
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 106of 115
Protocol 17Aug 2022
CONFIDENTIALTable 10.c U nacceptable Contraception Methods
Methods that are unacceptable in anystudy requiring contraception
Periodic abstinence (calendar, symptothermal, post -ovulation methods) 
Withdrawal ( coitus interruptus ) 
Spermicides only
Lactatio nal amenorrhea method 
Use of both female condom and male condom together at the same time
Contraceptives that are effective but have a failure rate of >1% per year when used consistently and correctly 
are insufficient in a study requiring highly effective contraception (ie, <1 % failure rate)
Progestogen -only  oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
Male or female condom with or without spermicide
Cap, diaphragm or sponge with spermicide
In addit ion, male parti cipants m ust b e advised not to donate sperm fro m signing of the ICF to  
days after the l ast dose of study  drug.
10.4.3. Pregnancy
If any participant is found to be pregnant during the study , the participant should be withdrawn 
and any  sponsor -supplied intervent ion(s) shoul d be immediately discont inued .
If a participant’s partner beco mes pregnant during the study  or wi thin days 
after the l ast dose, the participant’s partner should be asked for consent to record and fo llow the 
pregnan cy. 
If the pregnancy  occurs during or after administration of blinded intervent ion(s), the invest igator 
must inform the participant of their right to receive treatment informat ion. If the participant 
chooses to receive unblinded treatment informat ion, the individual blind should be broken by the 
investigator.
If the pregnant participant or the participant’s pregnant partner agrees, the invest igator should 
notify their primary  care physician that the participant/participant’s partner was participat ing in a 
clinical study  when they  became pregnant and provide details about the intervent ion the 
participant received (blinded or unblinded, as applicable). 
If the pregnancy  occurs during administration of active study  intervent ion (eg, fro m Day 1) unt il 
the last follow-up, the pregnancy should be reported immediately, using a pregnancy notificat ion 
form, to the contact listed in the contact informat ion list.
Pregnancies for which regulatory  reporting is not required include:
Pregnancies that occurred during the pr etreatm ent phase.
Pregnancies in participants (or their partners) who were unblinded and found to be 
rando mized to placebo.
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 110of 115
Protocol 17Aug 2022
CONFIDENTIALIB investigator’s brochure
ICF informed consent form (including electronic consent where applicable)
ICH International Council for Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
ICSD -3 International Classification of Sleep Disorders, 3rd Edition
IEC independent ethics committee
IRB institutional review board
IRT Interactive Response Technology
LTE long-term extension
MDE major depressive episode
MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed model for repeated measures
MSLT multiple sleep latency test
MWT Maintenance of Wakefulness Test
NT1 narcolepsy type 1
NT2 narcolepsy type 2
OX orexin
OX1R orexin type -1 receptor
OX2R orexin type -2 receptor
PD pharmacodynamic(s)
PI principal investigator
PK pharmacokinetic(s)
PSG polysomnography
QD once daily
QTcF QT interval with Fridericia correction method
REM rapid eye movement
RSI reference safety information
SAE serious adverse event
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 111of 115
Protocol 17Aug 2022
CONFIDENTIALSOA schedule of activities
SOREMP sleep onset REM period
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
ULN upper limit of normal
WCR weekly cataplexy rate
10.8 Protocol Amendment History 
Date Document Global/Country/Site Specific
17 Aug 2022 Original Protocol Global 
For non-commercial use only
For non-commercial use only
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 114of 115
Protocol 17Aug 2022
CONFIDENTIALAppendix 2:
For non-commercial use only
TAK -861
Study No. TAK -861-2001 Page 115of 115
Protocol 17Aug 2022
CONFIDENTIALAppendix 3:ICSD -3 Criteria for NT1
The cri teria for NT1 (narcol epsy wi th catapl exy) are as follows: Cri teria a) and b) m ust be met.
a)The parti cipant has daily  periods of  irrepressible need to sl eep or daytime lapses into sleep 
occurring for at least 3 months.
b)The presence of 1 and 2 or 3 of the fo llowing:
1.Cataplexy  (as defined under essent ia
l features).
2.A mean sleep latency o f ≤8minutes and 2 or more SOREMPs on a MSLT performed 
according to standard techniques. A SOREMP (defined as the appearance of REM sleep 
within 15 minutes of sleep onset) on the preceding nocturnal polyso mnogram may 
replace 1 of the SOREMPs on the MSLT.
3.The cerebrospinal fluid hypocretin -1 concentration, measured by immunoreactivit y, is 
either ≤110 pg/mL or l ess than one -third of  the m ean values obtained in normal 
participants wi th the sam e standardi zed assay.
For non-commercial use only